公开(公告)号：US20210198345A1

公开(公告)日：2021-07-01

申请号：US17196498

申请日：2021-03-09

申请人： VHSQUARED LIMITED

发明人： Scott Crowe ,  Mike West ,  Kevin Roberts

IPC分类号： C07K16/12 ,  C07K16/24

摘要： There is provided inter alia a construct suitable for oral administration comprising a first polypeptide and a second polypeptide connected by a labile peptide linker, wherein the labile peptide linker is labile to one or more proteases present in the intestinal tract and wherein the first and second polypeptides are substantially resistant to said one or more proteases.

公开(公告)号：US20180037639A1

公开(公告)日：2018-02-08

申请号：US15717174

申请日：2017-09-27

申请人： VHSQUARED LIMITED

发明人： Scott Crowe ,  Mike West ,  Kevin Roberts

IPC分类号： C07K16/12 ,  C07K16/24

CPC分类号： C07K16/1282 ,  C07K16/241 ,  C07K2317/56 ,  C07K2317/64 ,  C07K2317/94 ,  C07K2319/50

摘要： There is provided inter alia a construct suitable for oral administration comprising a first polypeptide and a second polypeptide connected by a labile peptide linker, wherein the labile peptide linker is labile to one or more proteases present in the intestinal tract and wherein the first and second polypeptides are substantially resistant to said one or more proteases.

公开(公告)号：US20180009881A1

公开(公告)日：2018-01-11

申请号：US15717230

申请日：2017-09-27

申请人： VHSQUARED LIMITED

发明人： Scott Crowe ,  Mike West ,  Kevin Roberts ,  Tim Carlton

IPC分类号： C07K16/12 ,  C07K16/24 ,  C07K16/28

CPC分类号： C07K16/1282 ,  A61K2039/542 ,  C07K16/241 ,  C07K16/2866 ,  C07K2317/22 ,  C07K2317/35 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/94 ,  Y02A50/472 ,  Y02A50/484

摘要： There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (CDR1-CDR3) and four framework regions, wherein: (a) at least one lysine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue; wherein the polypeptide has increased intestinal stability relative to a corresponding polypeptide not having said histidine substitutions.

公开(公告)号：US20180100008A1

公开(公告)日：2018-04-12

申请号：US15717214

申请日：2017-09-27

申请人： VHSQUARED LIMITED

发明人： Scott Crowe ,  Mike West ,  Kevin Roberts ,  Tim Carlton ,  Nika Strokappe ,  Theo Verrips

IPC分类号： C07K16/12 ,  C07K16/46

CPC分类号： C07K16/1282 ,  A61K2039/505 ,  C07K14/33 ,  C07K16/468 ,  C07K2317/22 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to Clostridium difficile toxin B.

公开(公告)号：US20200317769A1

公开(公告)日：2020-10-08

申请号：US16821287

申请日：2020-03-17

申请人： VHSQUARED LIMITED

发明人： Scott Crowe ,  Mike West ,  Kevin Roberts ,  Tim Carlton ,  Luana Maggiore ,  Marion Cubitt ,  Keith Ray

IPC分类号： C07K16/24 ,  A61K45/06 ,  A61K31/713 ,  A61K9/19 ,  A61K31/606 ,  A61K9/00 ,  A61K31/7088 ,  A61K38/00

摘要： There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to TNF-alpha, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.

公开(公告)号：US10772839B2

公开(公告)日：2020-09-15

申请号：US16140843

申请日：2018-09-25

申请人： VHSQUARED LIMITED

发明人： Scott Crowe ,  Mike West ,  Kevin Roberts ,  Tim Carlton ,  Luana Maggiore ,  Marion Cubitt ,  Gary Whale ,  John Wahlich ,  Mike Frodsham

IPC分类号： A61K9/20 ,  A61K9/14 ,  A61K9/50 ,  A61K9/16 ,  A61K9/28 ,  A61K9/48 ,  A61K9/00

摘要： There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.

公开(公告)号：US20170002069A1

公开(公告)日：2017-01-05

申请号：US15273353

申请日：2016-09-22

申请人： VHsquared Limited

发明人： Scott Crowe ,  Mike West ,  Kevin Roberts ,  Tim Carlton ,  Luana Maggiore ,  Marion Cubitt ,  Keith Ray

IPC分类号： C07K16/24

CPC分类号： C07K16/241 ,  A61K9/0014 ,  A61K9/19 ,  A61K31/606 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/00 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/542 ,  C07K2317/22 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

摘要： There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to TNF-alpha, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.

摘要翻译： 提供了包含结合TNF-α的免疫球蛋白链可变结构域的多肽，其中免疫球蛋白链可变结构域包含三个互补决定区（CDR1-CDR3）和四个构架区（FR1-FR4），其中CDR1-CDR3 和FR1-FR4如说明书中所定义。

公开(公告)号：US10980748B2

公开(公告)日：2021-04-20

申请号：US16988506

申请日：2020-08-07

申请人： VHsquared Limited

发明人： Scott Crowe ,  Mike West ,  Kevin Roberts ,  Tim Carlton ,  Luana Maggiore ,  Marion Cubitt ,  Gary Whale ,  John Wahlich ,  Mike Frodsham

IPC分类号： A61K9/20 ,  A61K9/14 ,  A61K9/50 ,  A61K9/16 ,  A61K9/28 ,  A61K9/48 ,  A61K9/00

摘要： There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.

公开(公告)号：US20200368167A1

公开(公告)日：2020-11-26

申请号：US16988506

申请日：2020-08-07

申请人： VHsquared Limited

发明人： Scott Crowe ,  Mike West ,  Kevin Roberts ,  Tim Carlton ,  Luana Maggiore ,  Marion Cubitt ,  Gary Whale ,  John Wahlich ,  Mike Frodsham

IPC分类号： A61K9/20 ,  A61K9/14 ,  A61K9/50 ,  A61K9/16 ,  A61K9/28 ,  A61K9/48

摘要： There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.

公开(公告)号：US20190008778A1

公开(公告)日：2019-01-10

申请号：US16140843

申请日：2018-09-25

申请人： VHSQUARED LIMITED

发明人： Scott Crowe ,  Mike West ,  Kevin Roberts ,  Tim Carlton ,  Luana Maggiore ,  Marion Cubitt ,  Gary Whale ,  John Wahlich ,  Mike Frodsham

IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K9/48

摘要： There is provided a solid pharmaceutical composition for delivering by oral administration a pharmaceutically active binding polypeptide to a region of the intestinal tract comprising a compressed core, wherein the compressed core comprises a pharmaceutically active binding polypeptide and wherein the compressed core is coated with a pH sensitive enteric coating.